MVC COVID-19 vaccine

MVC COVID-19 Vaccine

The MVC COVID-19 Vaccine is a vaccine developed for the prevention of the coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The vaccine was developed by the Medigen Vaccine Biologics Corporation (MVC), a biopharmaceutical company based in Taiwan.

Development

The MVC COVID-19 Vaccine, also known as MVC-COV1901, is a protein subunit vaccine. It uses a recombinant spike protein, which is the same protein that the SARS-CoV-2 virus uses to enter human cells. This protein is produced in the laboratory and then injected into the body to stimulate an immune response.

Efficacy

The efficacy of the MVC COVID-19 Vaccine has been evaluated in several clinical trials. According to the data released by MVC, the vaccine has shown promising results in terms of safety and efficacy.

Distribution and Administration

The MVC COVID-19 Vaccine is administered in two doses, with a gap of 28 days between the first and second dose. The vaccine is stored at a temperature between 2 and 8 degrees Celsius, which makes it easier to distribute and administer compared to some other COVID-19 vaccines.

Side Effects

As with all vaccines, the MVC COVID-19 Vaccine can cause side effects. The most common side effects reported in the clinical trials were pain at the injection site, fatigue, headache, muscle pain, and chills.

See Also

• COVID-19 pandemic
• COVID-19 vaccine
• Medigen Vaccine Biologics Corporation
• Clinical trial
• SARS-CoV-2